Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711061 · ClinicalTrials.gov registry record
Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy
A clinical trial of Growth Hormone Deficiency, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT00711061 is a study of Growth Hormone Deficiency that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 24 participants, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00711061, a study of Growth Hormone Deficiency, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the cardiovascular risks of growth hormone deficient young adult males who have completed growth hormone therapy to healthy young adult males.
Conditions Studied
Study Locations (1)
Missouri
- Childrens Mercy Hospitals and Clinics - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711061
The ClinicalTrials.gov registry entry for NCT00711061 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (94% lower). The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT00711061 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00711061 about?
NCT00711061 is a clinical study titled "Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy". The purpose of this study is to compare the cardiovascular risks of growth hormone deficient young adult males who have completed growth hormone therapy to healthy young adult males.
What is the current status of trial NCT00711061?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2008-06. Estimated completion is 2009-02.
What conditions does trial NCT00711061 study?
This clinical trial studies the following conditions: Growth Hormone Deficiency.
Who is sponsoring clinical trial NCT00711061?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00711061 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Hormone Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
RECRUITING
-
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
RECRUITING
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Chromosome 18 Clinical Research Center
RECRUITING
-
Growth Hormone Replacement Therapy for Retried Professional Football Players
RECRUITING · Phase 2
-
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.